Researchers determine a complex immune infiltrate pattern based on a newly constructed immune map developed using pancreatic ...

The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...

Massachusetts, USA-based cell therapy specialist Abcuro today announced the closing of a $200 million Series C financing.

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Despite the failure of an eczema trial in December, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky.

At Week 14, 69% (71% of b/tsDMARD-naïve and 66% of b/tsDMARD-experienced) or 220 of the 318 rosnilimab-treated patients across all doses achieved CDAI LDA and were eligible to remain on continued ...

Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international ...

Researchers sought to determine whether teclistamab would lead to a clinical response in patients with relapsed/refractory multiple myeloma.

US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...